COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,050 Articles (22,627 medRxiv, 8,423 bioRxiv)

Most recent first Previous |  Page 1738: Articles 17371-17380  | Next

Meta-Research: Citation needed? Wikipedia and the COVID-19 pandemic
Benjakob, O., Aviram, R., Sobel, J. A.
10.1101/2021.03.01.433379 — Posted: 2021-03-01 Discussion: Offsite
The impact of mutations on the structural and functional properties of SARS-CoV-2 proteins: A comprehensive bioinformatics analysis
Ikram, A., Naz, A., Awan, F., Rauff, B., Obaid, A., Hakim, M. S., Malik, A.
10.1101/2021.03.01.433340 — Posted: 2021-03-01
CD47 as a potential biomarker for the early diagnosis of severe COVID-19
McLaughlin, K.-M., Bojkova, D., Bechtel, M., Kandler, J., Reus, P., Le, T., Wagner, J. U., Ciesek, S., Wass, M. N., Michaelis, M., Cinatl, J. N.
10.1101/2021.03.01.433404 — Posted: 2021-03-01
Structural O-Glycoform Heterogeneity of the SARS-CoV-2 Spike Protein Receptor-Binding Domain Revealed by Native Top-Down Mass Spectrometry
Roberts, D. S., Mann, M. W., Melby, J. A., Larson, E. J., Zhu, Y., Brasier, A. R., Jin, S., Ge, Y.
10.1101/2021.02.28.433291 — Posted: 2021-03-01
Day-night and seasonal variation of human gene expression across tissues
Wucher, V., Sodaei, R., Amador, R., Irimia, M., Guigo, R.
10.1101/2021.02.28.433266 — Posted: 2021-03-01
A Comparison of Performance for Different SARS-Cov-2 Sequencing Protocols
Bermudez, J.
10.1101/2021.03.01.433428 — Posted: 2021-03-01
The E3 Ubiquitin Ligase RNF5 Facilitates SARS-CoV-2 Membrane Protein-Mediated Virion Release
Yuan, Z., Ding, B.
10.1101/2021.02.28.433287 — Posted: 2021-03-01
Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell
Puray-Chavez, M., Lapak, K. M., Schrank, T. P., Elliott, J. L., Bhatt, D. P., Agajanian, M. J., Jasuja, R., Lawson, D. Q., Davis, K., Rothlauf, P. W., Jo, H., Lee, N., Tenneti, K., Eschbach, J. E., Shema Mugisha, C., Vuong, H. R., Bailey, A. L., Hayes, D. N., Whelan, S. P. J., Horani, A., Brody, S. L., Goldfarb, D., Major, M. B., Kutluay, S. B.
10.1101/2021.03.01.433431 — Posted: 2021-03-01
Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees.
Tarke, A., Sidney, J., Methot, N., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., da Silva Antunes, R., Fraizer, A., Rawlings, S. A., Smith, D. M., Peters, B., Scheuermann, R. H., Weiskopf, D., Crotty, S., Grifoni, A., Sette, A.
10.1101/2021.02.27.433180 — Posted: 2021-03-01 Discussion: Onsite | Offsite
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
Faulkner, N., Ng, K., Wu, M., Harvey, R., Hussain, S., Greco, M., Bolland, W., Warchal, S., Margaritis, M., Paraskevopoulou, S., Heaney, J., Rickman, H., Houlihan, C., Spyer, M., Frampton, D., Byott, M., de Oliveira, T., Sigal, A., Kjaer, S., Swanton, C., Gandhi, S., Beale, R., Gamblin, S., Mccauley, J., Daniels, R., Howell, M., Bauer, D., Nastouli, E., Kassiotis, G.
10.1101/2021.03.01.433314 — Posted: 2021-03-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).